Patient portal frustrations revealed

The leading causes of frustration with patient portals are unresponsive staff and poor interfaces, according to a survey by technology consulting firm Software Advice.

But that is among those who have access to portals. Of the 1,540 U.S. patients surveyed by the firm, only one-third had known access to a portal.

Slow staff response times may stem from the relative novelty of patient portals. “Figuring out how to incorporate the demands of technology into an already packed day may prove challenging; even more so considering some physicians are resisting these changes,” according to the survey.

Automatic emails, often viewed as annoying and impersonal, also were strongly disliked by patients. Medical jargon in patient notes was often cited as a point of confusion, but only 11 percent of patients surveyed said it would frustrate them most when using a portal.

The survey also revealed gender differences when it comes to the most requested patient portal features. Male patients valued online scheduling and prescription refill requests while female patients expressed an interest in viewing lab results and making payments. Also, younger patients also had distinct preferences compared to their older counterparts. Patients ages 18-24 tended to value looking at lab results more than older patients.

The firm highlighted the following tips for providers to improve the patient portal experience:

  • Ensure features align with practice demographics
  • Take it for a test drive
  • Consider future patient preferences

Read the study here.

 

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.